US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

12.54

+1.1810.39%

Post-market: 12.49-0.0500-0.40%17:01 EDT

Volume:703.48K

Turnover:8.65M

Market Cap:581.58M

PE:-2.48

High:12.74

Open:11.47

Low:11.35

Close:11.36

52wk High:40.43

52wk Low:9.10

Shares:46.38M

Float Shares:13.40M

Volume Ratio:1.17

T/O Rate:5.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0580

EPS(LYR):-18.5643

ROE:-111.55%

ROA:-67.11%

PB:1.67

PE(LYR):-0.68

Loading ...

Overview Company News Filings

MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)

MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate

Benzinga Earnings

Maplight Therapeutics Q1 FY26 net loss widens to $60.67 million from year-ago quarter

Maplight Therapeutics Inc: Q1 EPS $-1.34

THOMSON REUTERS

Press Release: MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics management to meet with Needham

Maplight CMO Erin Pennock Foff sells USD 126,664 common shares

Maplight Therapeutics General Counsel Kristopher Hanson sells shares worth $421,760.64

Maplight CSO Lillie James Woodruff sells 721 shares worth $20,391.88

MapLight Therapeutics to present at RBCCM Global Healthcare Conference

Maplight Therapeutics General Counsel Kristopher Hanson disposes 13,917 shares worth $387,263.71

Maplight CFO Vishwas Setia disposes shares worth $1,003,511.53

Maplight CMO Erin Pennock Foff disposes of USD 1.63 million common shares

Maplight CEO Christopher Kroeger sells USD 1.38 million common shares

Maplight CSO Lillie James Woodruff sells USD 1.43 million common shares

HC Wainwright Initiates Coverage on MapLight Therapeutics With Buy Rating, $45 Price Target

MT Newswires Live

MapLight Therapeutics Initiated at Buy by HC Wainwright & Co.

MapLight Therapeutics initiated with a Buy at H.C. Wainwright

Needham Reaffirms Their Buy Rating on MapLight Therapeutics, Inc. (MPLT)

MapLight completes enrollment in Phase 2 ZEPHYR schizophrenia trial for ML-007C-MA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/MPLT/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MPLT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","market":"US","secType":"STK","nameCN":"MapLight Therapeutics, Inc.","latestPrice":12.54,"timestamp":1787688000000,"preClose":11.36,"halted":0,"volume":703477,"hourTrading":{"tag":"盘后","latestPrice":12.49,"preClose":12.54,"latestTime":"17:01 EDT","volume":2648,"amount":33204.360327999995,"timestamp":1787691661523,"change":-0.05,"changeRate":-0.003987,"amplitude":0.019139},"delay":0,"changeRate":0.1038732394366197,"floatShares":13402700,"shares":46377800,"eps":-5.058,"marketStatus":"Post-Mkt","change":1.18,"latestTime":"08-25 18:58:51 EDT","open":11.47,"high":12.74,"low":11.35,"amount":8645825.188964,"amplitude":0.122359,"askPrice":12.49,"askSize":59,"bidPrice":12,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.058,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1761537600000,"exchange":"NASDAQ","adjPreClose":11.36,"preHourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":11.36,"latestTime":"08:41 EDT","volume":11,"amount":127.200007,"timestamp":1787661716366,"change":0.14,"changeRate":0.012324,"amplitude":0.008803},"postHourTrading":{"tag":"盘后","latestPrice":12.49,"preClose":12.54,"latestTime":"17:01 EDT","volume":2648,"amount":33204.360327999995,"timestamp":1787691661523,"change":-0.05,"changeRate":-0.003987,"amplitude":0.019139},"volumeRatio":1.173052,"impliedVol":0.9739,"impliedVolPercentile":0.1967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MPLT\",,,,,undefined,":{"symbol":"MPLT","floatShares":13402700,"roa":"-67.11%","roe":"-111.55%","lyrEps":-18.564313,"volumeRatio":1.173052,"shares":46377800,"dividePrice":0,"high":12.74,"amplitude":0.122359,"preClose":11.36,"low":11.35,"week52Low":9.1,"pbRate":"1.67","week52High":40.43,"institutionHeld":0,"latestPrice":12.54,"committee":0.257862,"eps":-5.058,"divideRate":0,"volume":703477,"delay":0,"ttmEps":-5.058,"open":11.47,"prevYearClose":17.565,"prevWeekClose":11.21,"prevMonthClose":13.02,"prevQuarterClose":35.84,"fiveDayClose":11.82,"twentyDayClose":12.31,"sixtyDayClose":29.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MPLT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"MPLT","fiscalQuarterEnding":"2026/06","expectedEps":-1.4,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-05-14","symbol":"MPLT","fiscalQuarterEnding":"2026/03","expectedEps":-0.91,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-1.34},{"market":"US","date":"2026-03-26","symbol":"MPLT","fiscalQuarterEnding":"2025/12","expectedEps":-1.05,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-2.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MPLT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MPLT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3571,"buy":0.5,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":14,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MPLT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MPLT","date":"2026-08-24","current":-2.423883,"percent":0.995122,"low":-9.047313,"twenty":-8.09314,"median":-7.453371,"eighty":-6.435493,"high":-2.251599,"avg":-6.983343,"sd":1.608374,"marketCap":519895496},"quantilePoints":[{"date":"2025-10-31","current":-8.673514,"twenty":-8.310978,"median":-7.61973,"eighty":-7.489746,"marketCap":801692922},{"date":"2025-11-07","current":-7.620605,"twenty":-8.035178,"median":-7.644213,"eighty":-7.545137,"marketCap":704372551},{"date":"2025-11-14","current":-6.742394,"twenty":-7.98511,"median":-7.554503,"eighty":-7.23627,"marketCap":623199506},{"date":"2025-11-21","current":-6.274959,"twenty":-7.73109,"median":-7.394197,"eighty":-6.810384,"marketCap":579994498},{"date":"2025-11-28","current":-6.435493,"twenty":-7.639491,"median":-7.190943,"eighty":-6.54881,"marketCap":594832581},{"date":"2025-12-05","current":-7.783335,"twenty":-7.714027,"median":-7.115398,"eighty":-6.435493,"marketCap":800383679},{"date":"2025-12-12","current":-8.528142,"twenty":-7.986054,"median":-7.394197,"eighty":-6.45249,"marketCap":876974375},{"date":"2025-12-19","current":-8.462361,"twenty":-8.266224,"median":-7.554503,"eighty":-6.54881,"marketCap":870209954},{"date":"2025-12-26","current":-7.689969,"twenty":-8.289163,"median":-7.620605,"eighty":-6.624355,"marketCap":790782566},{"date":"2026-01-02","current":-7.454432,"twenty":-8.20424,"median":-7.61973,"eighty":-6.670627,"marketCap":766561577},{"date":"2026-01-09","current":-7.295285,"twenty":-8.111814,"median":-7.53948,"eighty":-6.75706,"marketCap":750196044},{"date":"2026-01-16","current":-7.84275,"twenty":-8.074467,"median":-7.609335,"eighty":-6.818055,"marketCap":806493478},{"date":"2026-01-23","current":-7.885189,"twenty":-7.999774,"median":-7.554503,"eighty":-6.827382,"marketCap":810857620},{"date":"2026-01-30","current":-7.885189,"twenty":-8.004018,"median":-7.620167,"eighty":-6.893484,"marketCap":810857620},{"date":"2026-02-06","current":-6.662942,"twenty":-7.999774,"median":-7.609335,"eighty":-6.893484,"marketCap":685170325},{"date":"2026-02-13","current":-7.308017,"twenty":-7.988887,"median":-7.547968,"eighty":-7.020967,"marketCap":751505286},{"date":"2026-02-20","current":-7.605091,"twenty":-7.988887,"median":-7.532944,"eighty":-7.096512,"marketCap":782054282},{"date":"2026-02-27","current":-7.392895,"twenty":-7.98511,"median":-7.541432,"eighty":-7.116712,"marketCap":760233571},{"date":"2026-03-06","current":-7.622066,"twenty":-7.966096,"median":-7.547968,"eighty":-7.127226,"marketCap":783799939},{"date":"2026-03-13","current":-8.122848,"twenty":-7.991064,"median":-7.592359,"eighty":-7.180699,"marketCap":835296817},{"date":"2026-03-20","current":-7.422602,"twenty":-8.000623,"median":-7.590237,"eighty":-7.203617,"marketCap":763288470},{"date":"2026-03-27","current":-5.207658,"twenty":-7.991064,"median":-7.583871,"eighty":-7.203617,"marketCap":839224545},{"date":"2026-04-02","current":-5.640953,"twenty":-7.988887,"median":-7.541432,"eighty":-7.116384,"marketCap":909050820},{"date":"2026-04-10","current":-7.964495,"twenty":-7.986054,"median":-7.516065,"eighty":-6.867043,"marketCap":1283494221},{"date":"2026-04-17","current":-7.720766,"twenty":-7.972363,"median":-7.507481,"eighty":-6.969974,"marketCap":1244216941},{"date":"2026-04-24","current":-7.883252,"twenty":-7.986054,"median":-7.516065,"eighty":-7.077626,"marketCap":1270401794},{"date":"2026-05-01","current":-8.966125,"twenty":-8.009111,"median":-7.554503,"eighty":-7.116384,"marketCap":1444908993},{"date":"2026-05-08","current":-8.214962,"twenty":-8.052399,"median":-7.590237,"eighty":-7.121808,"marketCap":1323857628},{"date":"2026-05-15","current":-6.658186,"twenty":-8.072823,"median":-7.605091,"eighty":-7.121808,"marketCap":1328174850},{"date":"2026-05-22","current":-6.655912,"twenty":-8.056678,"median":-7.585993,"eighty":-6.867043,"marketCap":1327721393},{"date":"2026-05-29","current":-6.769572,"twenty":-8.053247,"median":-7.547968,"eighty":-6.753265,"marketCap":1350394231},{"date":"2026-06-05","current":-6.842314,"twenty":-8.050011,"median":-7.507675,"eighty":-6.705014,"marketCap":1364904847},{"date":"2026-06-12","current":-6.899144,"twenty":-8.036085,"median":-7.484139,"eighty":-6.662816,"marketCap":1376241266},{"date":"2026-06-18","current":-6.64,"twenty":-8.014204,"median":-7.474515,"eighty":-6.654094,"marketCap":1324547195},{"date":"2026-06-26","current":-7.265128,"twenty":-8.003169,"median":-7.454432,"eighty":-6.652876,"marketCap":1449247804},{"date":"2026-07-02","current":-8.201684,"twenty":-8.01675,"median":-7.469285,"eighty":-6.653639,"marketCap":1636071990},{"date":"2026-07-10","current":-9.047313,"twenty":-8.054945,"median":-7.484139,"eighty":-6.655912,"marketCap":1804757904},{"date":"2026-07-17","current":-8.460828,"twenty":-8.122848,"median":-7.507675,"eighty":-6.658186,"marketCap":1687766060},{"date":"2026-07-24","current":-8.008463,"twenty":-8.137812,"median":-7.547968,"eighty":-6.662732,"marketCap":1597528165},{"date":"2026-07-31","current":-3.189291,"twenty":-8.129236,"median":-7.516065,"eighty":-6.653448,"marketCap":636199834},{"date":"2026-08-07","current":-3.018802,"twenty":-8.123697,"median":-7.486261,"eighty":-6.561799,"marketCap":602190577},{"date":"2026-08-14","current":-2.692276,"twenty":-8.099082,"median":-7.474515,"eighty":-6.526795,"marketCap":537055294},{"date":"2026-08-21","current":-2.266153,"twenty":-8.09314,"median":-7.454432,"eighty":-6.435493,"marketCap":520823053},{"date":"2026-08-24","current":-2.262117,"twenty":-8.09314,"median":-7.453371,"eighty":-6.435493,"marketCap":519895496}],"updateTime":1787679711868},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MPLT\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635562729","title":"MapLight Therapeutics reports Q1 EPS ($1.34), consensus ($1.12)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635562729","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635562729?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:45","pubTimestamp":1778791503,"startTime":"0","endTime":"0","summary":"“We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials,”...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-reports-q1-eps-1-34-consensus-1-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-reports-q1-eps-1-34-consensus-1-12-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635272642","title":"MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635272642","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635272642?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:44","pubTimestamp":1778791445,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over losses of $(29.33) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52582713/maplight-therapeutics-q1-eps-1-34-misses-1-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725291","title":"Maplight Therapeutics Q1 FY26 net loss widens to $60.67 million from year-ago quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725291","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725291?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:27","pubTimestamp":1778790437,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics posted a net loss of USD 60.67 million for the quarter ended March 31, 2026, widening from USD 22.34 million a year earlier.Operating loss widened to USD 64.5 million as operating expenses more than doubled to USD 64.5 million.Research and development expense climbed to USD 53.68 million, driven by higher clinical trial costs of USD 24.82 million and employee-related expense of USD 15.99 million.General and administrative expense rose to USD 10.82 million on higher employee-related costs of USD 6.99 million.Cash, cash equivalents and investments totaled USD 395.2 million at March 31, 2026; ZEPHYR Phase 2 schizophrenia trial completed enrollment with 307 participants, with topline results expected by mid-August 2026, while IRIS Phase 2 ASD trial topline data are also expected by mid-August 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL2rQGJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635264297","title":"Maplight Therapeutics Inc:  Q1 EPS $-1.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2635264297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635264297?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUABNZNJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723955","title":"Press Release: MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"-- Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in. schizophrenia, with topline results expected by mid-August 2026. -- Last patient visit completed for ML-004's Phase 2 IRIS trial in autism. -- Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's. disease psychosis, with topline results expected in the second half of. -- Ended the quarter with $395.2 million in cash, cash equivalents and. investments, which is expected to fund operations through 2027. \"We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials, \" said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. \"With topline results from both studies expected by mid-August, continued advancement of our VISTA trial in Alzheimer's disease psychosis and progress across our early-stage pipeline, MapLight is entering an important inflection point in our mission to improve the lives of patients living","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823421416.USD","LU1236620750.USD","BK4106","LU0061474705.USD","ADP","LU0390134368.USD","IE00BFSS7M15.SGD","LU1718418525.SGD","LU2506951958.HKD","LU2404859741.USD","LU2552382132.HKD","ABI","LU0494093205.USD","MPLT","BK4227","LU0820561818.USD","LU0198837287.USD","LU1803068979.SGD","SG9999000418.SGD","LU0234572021.USD","LU0690374615.EUR","LU1868837136.USD","LU1712237335.SGD","LU0965509283.SGD","BK4566","LU1989772840.SGD","SGXZ81514606.USD","LU2168564149.EUR","LU0061474960.USD","LU0957791311.USD","LU2896262040.SGD","LU0965509101.SGD","LU1236620834.HKD","IE00B1XK9C88.USD","LU0868494617.USD","LU0094547139.USD","LU0950375773.USD","LU2756315664.SGD","LU1363072403.SGD","LU0170899867.USD","LU1037948897.HKD","MA","IE000MB6IJN5.SGD","LU1228905540.USD","LU2023250330.USD","IE000SO60NU8.SGD","IE00B775H168.HKD","IE00B4JS1V06.HKD","IE000WAW04H5.SGD","LU2361044865.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240982","title":"MapLight Therapeutics management to meet with Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240982?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:10","pubTimestamp":1778616657,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 19 in New York hosted by Needham. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-management-to-meet-with-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-management-to-meet-with-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634252607","title":"Maplight CMO Erin Pennock Foff sells USD 126,664 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2634252607","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634252607?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549449,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Medical Officer Erin Pennock Foff sold 4,438 shares of voting common stock on May 7, 2026.Sales were executed at weighted average prices of USD 28.52 and USD 29.1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL1Z5Hwg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634252605","title":"Maplight Therapeutics General Counsel Kristopher Hanson sells shares worth $421,760.64","url":"https://stock-news.laohu8.com/highlight/detail?id=2634252605","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634252605?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549448,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics General Counsel Kristopher L. Hanson reported sales of 13,917 shares of voting common stock on May 11, 2026.Sales were reported at weighted average prices ranging from $27.61 to $30.56.Hanson’s direct holding fell to 162,331 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL81V4dw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight Therapeutics General Counsel Kristopher Hanson sells shares worth $421,760.64","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634252601","title":"Maplight CSO Lillie James Woodruff sells 721 shares worth $20,391.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2634252601","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634252601?lang=en_us&edition=fundamental","pubTime":"2026-05-12 09:30","pubTimestamp":1778549443,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Scientific Officer Lillie James Woodruff sold 721 shares of voting common stock on May 7, 2026 at USD 28.28 per share.Holdings in voting common stock stood at 242,729 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5WwzC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633301584","title":"MapLight Therapeutics to present at RBCCM Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633301584","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633301584?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:01","pubTimestamp":1778238113,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics management to present at RBCCM Global Healthcare Conference in New York on May 19, with 1x1 investor meetings.Participation set for Jefferies Global Healthcare Conference in New York on June 3, including a presentation, with 1x1 meetings.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9GxcYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","MPLT","BK4139","BK4585","NDAQ","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633094169","title":"Maplight Therapeutics General Counsel Kristopher Hanson disposes 13,917 shares worth $387,263.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2633094169","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633094169?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:16","pubTimestamp":1778112969,"startTime":"0","endTime":"0","summary":"Kristopher Hanson, general counsel at MapLight Therapeutics, sold 13,917 shares of voting common stock on May 4.Sales were priced between USD 27.5 and USD 30.08 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL87wbM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633216909","title":"Maplight CFO Vishwas Setia disposes shares worth $1,003,511.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2633216909","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633216909?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:16","pubTimestamp":1778112967,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics CFO Setia Vishwas reported sales of 36,371 shares of Voting Common Stock in transactions dated May 4-6.Sales were executed at weighted average prices ranging from $27.36 to $30.12.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDLbykcWR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633169097","title":"Maplight CMO Erin Pennock Foff disposes of USD 1.63 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633169097","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633169097?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:16","pubTimestamp":1778112961,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics Chief Medical Officer Erin Pennock Foff sold 50,280 shares of voting common stock in open-market transactions from May 4 to May 6.Sales prices ranged from USD 27.50 to USD 30.08 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9kB7FR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633770169","title":"Maplight CEO Christopher Kroeger sells USD 1.38 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633770169","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633770169?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:15","pubTimestamp":1778112959,"startTime":"0","endTime":"0","summary":"Maplight Therapeutics CEO Christopher A. Kroeger disclosed sales of 49,744 voting common shares on May 4-6.Sales priced between USD 27.5 and USD 29.13 per share across the transactions.Direct holdings fell to 1,580,820 shares following the sales.Filing also reported 101,190 shares held indirectly through a nominee trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1rDh8S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633697721","title":"Maplight CSO Lillie James Woodruff sells USD 1.43 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2633697721","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633697721?lang=en_us&edition=fundamental","pubTime":"2026-05-07 08:15","pubTimestamp":1778112954,"startTime":"0","endTime":"0","summary":"Lillie James Woodruff, Chief Scientific Officer, sold 51,707 shares of Voting Common Stock in transactions dated May 4-6.Sales were reported at weighted-average prices ranging from $27.5 to $30.08 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL7zJcw5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maplight CSO Lillie James Woodruff sells USD 1.43 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632953639","title":"HC Wainwright Initiates Coverage on MapLight Therapeutics With Buy Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2632953639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632953639?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:27","pubTimestamp":1777897625,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $34.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632937708","title":"MapLight Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2632937708","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632937708?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:12","pubTimestamp":1777893120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MPLT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 07:12 ET (11:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632932819","title":"MapLight Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2632932819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632932819?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:16","pubTimestamp":1777889814,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $45 price target MapLight is a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maplight-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632612374","title":"Needham Reaffirms Their Buy Rating on MapLight Therapeutics, Inc. (MPLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632612374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632612374?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:39","pubTimestamp":1777639190,"startTime":"0","endTime":"0","summary":"In a report released today, Ami Fadia from Needham reiterated a Buy rating on MapLight Therapeutics, Inc., with a price target of $37.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-maplight-therapeutics-inc-mplt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632619651","title":"MapLight completes enrollment in Phase 2 ZEPHYR schizophrenia trial for ML-007C-MA","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632619651?lang=en_us&edition=fundamental","pubTime":"2026-05-01 19:02","pubTimestamp":1777633348,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics completed enrollment in ZEPHYR Phase 2 trial of ML-007C-MA for schizophrenia, positioning program for near-term data readout.Topline results have not been presented; data from ZEPHYR expected by mid-August 2026.Separate IRIS Phase 2 trial of ML-004 in autism spectrum disorder finished final patient visit, moving study into analysis phase.IRIS topline results also scheduled for mid-August 2026, setting up a dual Phase 2 catalyst for MapLight.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6xlplg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":126,"code":"91000000","status":"200"}]}}